These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33460858)

  • 1. Factors Associated with Frequent Exacerbations in the UK Severe Asthma Registry.
    Yang F; Busby J; Heaney LG; Menzies-Gow A; Pfeffer PE; Jackson DJ; Mansur AH; Siddiqui S; Brightling CE; Niven R; Thomson NC; Chaudhuri R;
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2691-2701.e1. PubMed ID: 33460858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic oral corticosteroids use and persistent eosinophilia in severe asthmatics from the Belgian severe asthma registry.
    Graff S; Vanwynsberghe S; Brusselle G; Hanon S; Sohy C; Dupont LJ; Peche R; Michils A; Pilette C; Joos G; Louis RE; Schleich FN
    Respir Res; 2020 Aug; 21(1):214. PubMed ID: 32787967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of frequent exacerbations in (ex)smoking and never smoking adults with severe asthma.
    Westerhof GA; de Groot JC; Amelink M; de Nijs SB; Ten Brinke A; Weersink EJ; Bel EH
    Respir Med; 2016 Sep; 118():122-127. PubMed ID: 27578481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring the cost of poor asthma control and exacerbations.
    Sullivan PW; Ghushchyan VH; Campbell JD; Globe G; Bender B; Magid DJ
    J Asthma; 2017 Jan; 54(1):24-31. PubMed ID: 27286240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mepolizumab effectiveness and identification of super-responders in severe asthma.
    Harvey ES; Langton D; Katelaris C; Stevens S; Farah CS; Gillman A; Harrington J; Hew M; Kritikos V; Radhakrishna N; Bardin P; Peters M; Reynolds PN; Upham JW; Baraket M; Bowler S; Bowden J; Chien J; Chung LP; Grainge C; Jenkins C; Katsoulotos GP; Lee J; McDonald VM; Reddel HK; Rimmer J; Wark PAB; Gibson PG
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32139455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe asthma exacerbations in the United States:: Incidence, characteristics, predictors, and effects of biologic treatments.
    Trevor J; Lugogo N; Carr W; Moore WC; Soong W; Panettieri RA; Desai P; Trudo F; Ambrose CS
    Ann Allergy Asthma Immunol; 2021 Nov; 127(5):579-587.e1. PubMed ID: 34273485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes.
    McDowell PJ; Busby J; Hanratty CE; Djukanovic R; Woodcock A; Walker S; Hardman TC; Arron JR; Choy DF; Bradding P; Brightling CE; Chaudhuri R; Cowan D; Mansur AH; Fowler SJ; Diver SE; Howarth P; Lordan J; Menzies-Gow A; Harrison T; Robinson DS; Holweg CTJ; Matthews JG; Pavord ID; Heaney LG
    Am J Respir Crit Care Med; 2022 Sep; 206(5):545-553. PubMed ID: 35549845
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).
    Niven RM; Saralaya D; Chaudhuri R; Masoli M; Clifton I; Mansur AH; Hacking V; McLain-Smith S; Menzies-Gow A
    BMJ Open; 2016 Aug; 6(8):e011857. PubMed ID: 27507234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burden of Chronic Oral Corticosteroid Use by Adults with Persistent Asthma.
    Zeiger RS; Schatz M; Li Q; Chen W; Khatry DB; Tran TN
    J Allergy Clin Immunol Pract; 2017; 5(4):1050-1060.e9. PubMed ID: 28215604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe asthma management in the era of biologics: insights of the Italian Registry on Severe Asthma (IRSA).
    Bilò MB; Antonicelli L; Carone M; De Michele F; Menzella F; Musarra A; Tognella S; Vaghi A; Micheletto C
    Eur Ann Allergy Clin Immunol; 2021 May; 53(3):103-114. PubMed ID: 33728838
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
    Khurana S; Brusselle GG; Bel EH; FitzGerald JM; Masoli M; Korn S; Kato M; Albers FC; Bradford ES; Gilson MJ; Price RG; Humbert M
    Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of an OCS-dependent severe asthma population treated with mepolizumab.
    Prazma CM; Wenzel S; Barnes N; Douglass JA; Hartley BF; Ortega H
    Thorax; 2014 Dec; 69(12):1141-2. PubMed ID: 24834924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral corticosteroid stewardship: key insights from the Australasian Severe Asthma Registry.
    Politis J; Chung LP; Igwe E; Bardin P; Gibson PG
    Intern Med J; 2024 Jul; 54(7):1136-1145. PubMed ID: 38622806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational oral corticosteroid use in adult severe asthma: A narrative review.
    Chung LP; Upham JW; Bardin PG; Hew M
    Respirology; 2020 Feb; 25(2):161-172. PubMed ID: 31713955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults.
    Petsky HL; Li A; Chang AB
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD005603. PubMed ID: 28837221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Severe Asthma Hidden in UK Primary Care.
    Ryan D; Heatley H; Heaney LG; Jackson DJ; Pfeffer PE; Busby J; Menzies-Gow AN; Jones R; Tran TN; Al-Ahmad M; Backer V; Belhassen M; Bosnic-Anticevich S; Bourdin A; Bulathsinhala L; Carter V; Chaudhry I; Eleangovan N; FitzGerald JM; Gibson PG; Hosseini N; Kaplan A; Murray RB; Rhee CK; Van Ganse E; Price DB
    J Allergy Clin Immunol Pract; 2021 Apr; 9(4):1612-1623.e9. PubMed ID: 33309935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study.
    Menzies-Gow A; Gurnell M; Heaney LG; Corren J; Bel EH; Maspero J; Harrison T; Jackson DJ; Price D; Lugogo N; Kreindler J; Burden A; de Giorgio-Miller A; Faison S; Padilla K; Martin UJ; Garcia Gil E;
    Eur Respir J; 2022 Dec; 60(6):. PubMed ID: 35896216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A real-life comparative effectiveness study into the addition of antibiotics to the management of asthma exacerbations in primary care.
    Murray CS; Lucas SJ; Blakey J; Kaplan A; Papi A; Paton J; Phipatanakul W; Price D; Teoh OH; Thomas M; Turner S; Papadopoulos NG
    Eur Respir J; 2021 Jul; 58(1):. PubMed ID: 33419889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised controlled trial for the titration of oral corticosteroids using markers of inflammation in severe asthma.
    Ramsahai JM; Simpson JL; Cook A; Gibson PG; McDonald V; Grainge C; Heaney LG; Wark PA
    Thorax; 2023 Sep; 78(9):868-874. PubMed ID: 36948587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.